Novo Nordisk A/S (NVO)
$38.64+1.20%Close
SELLRECOVERY · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV23.4%–76.0%
- Market cap
- $171.7B
- Beta
- 0.35
- Div yield
- 4.79%
- P/E (TTM)
- 9.36
- IV-%ile
- 12
- IV ATM
- 30.8%
- Short % float
- 0.99%
- Days to cover
- 1.7
- SI change
- +20.1%
- 1W
- +3.54%
- 1M
- -12.20%
- vs SPY 1W
- +2.38%
- vs SPY 1M
- -15.19%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1169.93+0.83%
- JNJSELLJohnson & Johnson$618.1BBEARQ 22$256.48+1.93%
- ABBVBUYAbbVie Inc.$481.3BBULLQ 29$272.42+1.49%
- MRKSELLMerck & Co., Inc.$351.7BBEARQ 11$142.40+2.26%
- RHHBYRoche Holding AG$340.1B$53.36
- AZNSELLAstraZeneca PLC$246.2BRECOVERYQ 20$158.78+0.26%
- AMGNBUYAmgen Inc.$219.9BRECOVERYQ 22$407.44+1.82%
- PFESELLPfizer Inc.$158.6BBULLQ 13$27.82+1.65%
- SNYSELLSanofi$96.6BBEARQ 11$40.23-0.40%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.54-0.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NVO?
- LOPJLB’s latest quantitative signal on Novo Nordisk A/S (NVO) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is NVO in?
- Novo Nordisk A/S (NVO) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Novo Nordisk A/S (NVO) do?
- Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two …